{ "run": { "id": "cmnr12jqs02eyp65872tje4fo", "region": "US", "assetId": "cmnr12jq502eup658lb7pnzl8", "ticker": "BIIB", "snapshotId": "cmnr12jqd02ewp658jen7w8j3", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:19:49.104Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr12jqd02ewp658jen7w8j3", "assetId": "cmnr12jq502eup658lb7pnzl8", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 179.9, "dayLow": 176.35, "volume": 1254639, "dayHigh": 180.17, "currency": "USD", "prevClose": 175.61, "week52Low": 110.04, "week52High": 202.41 }, "fundamentals": { "pe": 19.9309173272933, "beta": 0.700801394780314, "epsTTM": 8.83, "fcfTTM": 1550600000, "growth": { "epsYoy": -0.2123104371097235, "revenueYoy": 0.0221891503632737 }, "sector": "Biological Products, (No Diagnostic Substances)", "margins": { "net": 0.29756184639186, "gross": 0.8657304791514809, "operating": 0.3384332743257516 }, "website": "https://biogen.com", "industry": "Biotechnology", "pegRatio": -0.938762954785538, "ebitdaTTM": 3204300000, "forwardPe": 11.8591644204852, "marketCap": 18378285308, "totalCash": 3008500000, "totalDebt": 6286800000, "debtEquity": 0.344353884579992, "quickRatio": 1.540007165462471, "revenueTTM": 13444600000, "companyName": "BIOGEN INC.", "priceToBook": 1.41221544849043, "currentRatio": 2.67931569833403, "dividendYield": null, "returnOnAssets": 0.1358922536048506, "returnOnEquity": 0.0708174488409798, "analystOpinions": null, "businessSummary": "Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).", "enterpriseValue": 29060835000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 7500, "sharesOutstanding": 146758528, "enterpriseToEbitda": 9.069324033330213, "analystTargetMedian": null, "enterpriseToRevenue": 2.161524701367092, "operatingCashflowTTM": 2204600000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:19:49.094Z" }, "results": [ { "id": "cmnr12jqv02f0p658avo9zz44", "runId": "cmnr12jqs02eyp65872tje4fo", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"BIIB\",\"currency\":\"USD\",\"current_price\":179.9,\"target_price_6m\":190,\"target_price_12m\":198,\"recommendation\":\"BUY\",\"confidence\":0.55,\"thesis_bullets\":[\"Forward P/E of ~11.9x signals market expects meaningful earnings recovery ahead\",\"EV/EBITDA at 9.1x is undemanding for large-cap biotech with strong cash generation\",\"Legacy MS franchise erosion remains key structural headwind on revenues\",\"Leqembi Alzheimer's uptake trajectory remains highly uncertain but optionality exists\",\"Cost restructuring and biosimilars growth provide partial offset to franchise declines\"],\"key_drivers\":[{\"driver\":\"Leqembi (lecanemab) commercial uptake trajectory\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"MS franchise (Tecfidera, Tysabri) revenue erosion\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Biosimilars portfolio revenue growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operational restructuring and headcount reduction\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Spinraza competition from gene therapies (Zolgensma)\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Skyclarys launch ramp in Friedreich's ataxia\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pipeline clinical readouts (neuropsych, rare disease)\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Net debt of ~$3.3B constraining capital deployment flexibility\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Leqembi reimbursement and adoption materially below expectations\",\"Accelerated generic/biosimilar erosion of MS portfolio\",\"Pipeline clinical trial failures reduce long-term growth optionality\",\"Regulatory or safety setbacks for key marketed products\",\"Macro healthcare policy changes impacting drug pricing\"],\"assumptions\":{\"revenue_cagr_3y\":0.02,\"ebit_margin_target\":0.35,\"wacc\":0.09,\"terminal_multiple\":10},\"scenarios\":{\"bear\":{\"target_price\":140,\"prob\":0.2,\"notes\":\"MS erosion accelerates, Leqembi disappoints, EPS compresses to ~$10-11 on low multiple.\"},\"base\":{\"target_price\":198,\"prob\":0.55,\"notes\":\"Modest revenue growth, cost savings drive EPS toward $15+, 13x forward earnings.\"},\"bull\":{\"target_price\":245,\"prob\":0.25,\"notes\":\"Leqembi inflection drives revenue reacceleration, pipeline catalysts expand multiple.\"}},\"method_notes\":\"Blended valuation: forward P/E (12-14x on estimated forward EPS ~$15) cross-checked with EV/EBITDA (9-11x). Base 12M target ~$198 implies ~10% upside, qualifying as BUY under rubric. Confidence at 0.55 reflects high uncertainty around Leqembi uptake and MS erosion pace. Sell-side targets noted but not used as inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Leqembi reimbursement and adoption materially below expectations", "Accelerated generic/biosimilar erosion of MS portfolio", "Pipeline clinical trial failures reduce long-term growth optionality", "Regulatory or safety setbacks for key marketed products", "Macro healthcare policy changes impacting drug pricing" ], "ticker": "BIIB", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Modest revenue growth, cost savings drive EPS toward $15+, 13x forward earnings.", "target_price": 198 }, "bear": { "prob": 0.2, "notes": "MS erosion accelerates, Leqembi disappoints, EPS compresses to ~$10-11 on low multiple.", "target_price": 140 }, "bull": { "prob": 0.25, "notes": "Leqembi inflection drives revenue reacceleration, pipeline catalysts expand multiple.", "target_price": 245 } }, "confidence": 0.55, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.02, "terminal_multiple": 10, "ebit_margin_target": 0.35 }, "key_drivers": [ { "driver": "Leqembi (lecanemab) commercial uptake trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "MS franchise (Tecfidera, Tysabri) revenue erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "Biosimilars portfolio revenue growth", "impact": "MED", "direction": "POS" }, { "driver": "Operational restructuring and headcount reduction", "impact": "MED", "direction": "POS" }, { "driver": "Spinraza competition from gene therapies (Zolgensma)", "impact": "MED", "direction": "NEG" }, { "driver": "Skyclarys launch ramp in Friedreich's ataxia", "impact": "MED", "direction": "POS" }, { "driver": "Pipeline clinical readouts (neuropsych, rare disease)", "impact": "MED", "direction": "POS" }, { "driver": "Net debt of ~$3.3B constraining capital deployment flexibility", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended valuation: forward P/E (12-14x on estimated forward EPS ~$15) cross-checked with EV/EBITDA (9-11x). Base 12M target ~$198 implies ~10% upside, qualifying as BUY under rubric. Confidence at 0.55 reflects high uncertainty around Leqembi uptake and MS erosion pace. Sell-side targets noted but not used as inputs. Not investment advice.", "current_price": 179.9, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of ~11.9x signals market expects meaningful earnings recovery ahead", "EV/EBITDA at 9.1x is undemanding for large-cap biotech with strong cash generation", "Legacy MS franchise erosion remains key structural headwind on revenues", "Leqembi Alzheimer's uptake trajectory remains highly uncertain but optionality exists", "Cost restructuring and biosimilars growth provide partial offset to franchise declines" ], "target_price_6m": 190, "target_price_12m": 198 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 33531, "createdAt": "2026-04-09T05:19:49.104Z", "usage": { "inputTokens": 3789, "outputTokens": 1712, "costUsd": 0.061745 } }, { "id": "cmnr12jqv02f3p658kfoyqcmm", "runId": "cmnr12jqs02eyp65872tje4fo", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Research_Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"BIIB\",\n \"currency\": \"USD\",\n \"current_price\": 179.9,\n \"target_price_6m\": 175.0,\n \"target_price_12m\": 185.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Mixed growth with EPS decline but revenue stability.\",\n \"Pipeline opportunities in neurological diseases.\",\n \"Patent risks for key multiple sclerosis drugs.\",\n \"New launches like Skyclarys providing incremental growth.\",\n \"Valuation near fair value with limited upside.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Pipeline advancements\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Patent cliffs for Tecfidera\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Competition in multiple sclerosis\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Growth of Spinraza\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"New drug launches (e.g., Skyclarys)\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Biosimilars market expansion\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n { \"driver\": \"Pricing pressures\", \"impact\": \"HIGH\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\"Clinical trial failures\", \"Regulatory setbacks\", \"Generic competition\", \"Market saturation\", \"Currency fluctuations\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.02,\n \"ebit_margin_target\": 0.34,\n \"wacc\": 0.085,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 150.0, \"prob\": 0.3, \"notes\": \"Patent cliffs and competition pressure.\" },\n \"base\": { \"target_price\": 185.0, \"prob\": 0.5, \"notes\": \"Stable performance with modest growth.\" },\n \"bull\": { \"target_price\": 220.0, \"prob\": 0.2, \"notes\": \"Successful pipeline launches drive upside.\" }\n },\n \"method_notes\": \"Valuation based on DCF with assumptions as labeled; recommendation HOLD due to limited upside and mixed evidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI_Equity_Research_Model", "risks": [ "Clinical trial failures", "Regulatory setbacks", "Generic competition", "Market saturation", "Currency fluctuations" ], "ticker": "BIIB", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Stable performance with modest growth.", "target_price": 185 }, "bear": { "prob": 0.3, "notes": "Patent cliffs and competition pressure.", "target_price": 150 }, "bull": { "prob": 0.2, "notes": "Successful pipeline launches drive upside.", "target_price": 220 } }, "confidence": 0.6, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.02, "terminal_multiple": 10, "ebit_margin_target": 0.34 }, "key_drivers": [ { "driver": "Pipeline advancements", "impact": "HIGH", "direction": "POS" }, { "driver": "Patent cliffs for Tecfidera", "impact": "HIGH", "direction": "NEG" }, { "driver": "Competition in multiple sclerosis", "impact": "MED", "direction": "NEG" }, { "driver": "Growth of Spinraza", "impact": "MED", "direction": "POS" }, { "driver": "New drug launches (e.g., Skyclarys)", "impact": "MED", "direction": "POS" }, { "driver": "Biosimilars market expansion", "impact": "LOW", "direction": "POS" }, { "driver": "Pricing pressures", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Valuation based on DCF with assumptions as labeled; recommendation HOLD due to limited upside and mixed evidence. Not investment advice.", "current_price": 179.9, "recommendation": "HOLD", "thesis_bullets": [ "Mixed growth with EPS decline but revenue stability.", "Pipeline opportunities in neurological diseases.", "Patent risks for key multiple sclerosis drugs.", "New launches like Skyclarys providing incremental growth.", "Valuation near fair value with limited upside." ], "target_price_6m": 175, "target_price_12m": 185 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 341, "createdAt": "2026-04-09T05:19:49.104Z", "usage": { "inputTokens": 2271, "outputTokens": 4219, "costUsd": 0.002408 } }, { "id": "cmnr12jqv02f1p658kdf474iv", "runId": "cmnr12jqs02eyp65872tje4fo", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_Biogen_Base\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"BIIB\",\n \"currency\": \"USD\",\n \"current_price\": 179.9,\n \"target_price_6m\": 190.0,\n \"target_price_12m\": 205.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Forward P/E of 11.8x prices in excessive pessimism regarding MS franchise erosion.\",\n \"Leqembi's Alzheimer's launch trajectory remains a critical, albeit slow-building, long-term growth catalyst.\",\n \"Skyclarys acquisition provides immediate revenue diversification and high-margin rare disease exposure.\",\n \"Strong FCF generation of $1.55B supports debt reduction and further pipeline business development.\",\n \"Cost-cutting initiatives are stabilizing operating margins despite top-line pressures from generic competition.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Leqembi adoption rate\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Tecfidera generic erosion\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Skyclarys sales ramp\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Spinraza market share vs competitors\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operating expense reduction program\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Pipeline readouts in immunology and neurology\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Slower-than-expected infrastructure readiness for Leqembi infusions.\",\n \"Faster-than-anticipated generic erosion of the legacy MS franchise.\",\n \"Regulatory setbacks or clinical trial failures in the mid-to-late stage pipeline.\",\n \"Increased competition in the SMA market impacting Spinraza revenues.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.015,\n \"ebit_margin_target\": 0.32,\n \"wacc\": 0.085,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 145.0,\n \"prob\": 0.25,\n \"notes\": \"Leqembi fails to gain traction and MS erosion accelerates rapidly.\"\n },\n \"base\": {\n \"target_price\": 205.0,\n \"prob\": 0.55,\n \"notes\": \"Steady Leqembi ramp and Skyclarys growth offset legacy MS declines.\"\n },\n \"bull\": {\n \"target_price\": 240.0,\n \"prob\": 0.2,\n \"notes\": \"Blockbuster Leqembi adoption and successful pipeline readouts drive multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on 13.5x forward P/E and 10x EV/EBITDA, reflecting a transition period. BUY rating due to ~14% upside to 12M target, balancing MS erosion against new product cycles. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearch_Biogen_Base", "risks": [ "Slower-than-expected infrastructure readiness for Leqembi infusions.", "Faster-than-anticipated generic erosion of the legacy MS franchise.", "Regulatory setbacks or clinical trial failures in the mid-to-late stage pipeline.", "Increased competition in the SMA market impacting Spinraza revenues." ], "ticker": "BIIB", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady Leqembi ramp and Skyclarys growth offset legacy MS declines.", "target_price": 205 }, "bear": { "prob": 0.25, "notes": "Leqembi fails to gain traction and MS erosion accelerates rapidly.", "target_price": 145 }, "bull": { "prob": 0.2, "notes": "Blockbuster Leqembi adoption and successful pipeline readouts drive multiple expansion.", "target_price": 240 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.015, "terminal_multiple": 10, "ebit_margin_target": 0.32 }, "key_drivers": [ { "driver": "Leqembi adoption rate", "impact": "HIGH", "direction": "POS" }, { "driver": "Tecfidera generic erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "Skyclarys sales ramp", "impact": "MED", "direction": "POS" }, { "driver": "Spinraza market share vs competitors", "impact": "MED", "direction": "NEG" }, { "driver": "Operating expense reduction program", "impact": "MED", "direction": "POS" }, { "driver": "Pipeline readouts in immunology and neurology", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on 13.5x forward P/E and 10x EV/EBITDA, reflecting a transition period. BUY rating due to ~14% upside to 12M target, balancing MS erosion against new product cycles. Not investment advice.", "current_price": 179.9, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of 11.8x prices in excessive pessimism regarding MS franchise erosion.", "Leqembi's Alzheimer's launch trajectory remains a critical, albeit slow-building, long-term growth catalyst.", "Skyclarys acquisition provides immediate revenue diversification and high-margin rare disease exposure.", "Strong FCF generation of $1.55B supports debt reduction and further pipeline business development.", "Cost-cutting initiatives are stabilizing operating margins despite top-line pressures from generic competition." ], "target_price_6m": 190, "target_price_12m": 205 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 24211, "createdAt": "2026-04-09T05:19:49.104Z", "usage": { "inputTokens": 2624, "outputTokens": 870, "costUsd": 0.015688 } }, { "id": "cmnr12jqv02ezp658jjcbqhtj", "runId": "cmnr12jqs02eyp65872tje4fo", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"BIIB\",\"currency\":\"USD\",\"current_price\":179.9,\"target_price_6m\":188.0,\"target_price_12m\":198.0,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"Forward P/E near 12x discounts much of legacy MS erosion.\",\"Leqembi, Skyclarys and biosimilars can stabilize the revenue mix.\",\"TTM operating margin above 33% supports resilient cash generation.\",\"EPS fell YoY and neuroscience launch execution risk remains elevated.\",\"Valuation looks modestly attractive, but uncertainty limits upside.\"],\"key_drivers\":[{\"driver\":\"Leqembi uptake and coverage\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"MS franchise erosion\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Spinraza stability\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Skyclarys and rare disease growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Cost discipline and margin retention\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pipeline readouts and approvals\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pricing and IRA reimbursement pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Deleveraging and capital allocation\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Faster-than-expected MS franchise declines\",\"Slower Leqembi adoption or safety-related setbacks\",\"Pipeline trial or regulatory disappointments\",\"Pricing pressure and reimbursement changes\",\"Manufacturing or supply disruptions\"],\"assumptions\":{\"revenue_cagr_3y\":0.03,\"ebit_margin_target\":0.31,\"wacc\":0.095,\"terminal_multiple\":13},\"scenarios\":{\"bear\":{\"target_price\":150,\"prob\":0.25,\"notes\":\"Legacy products decline faster and new launches underwhelm.\"},\"base\":{\"target_price\":198,\"prob\":0.55,\"notes\":\"New products partly offset erosion and valuation rerates modestly.\"},\"bull\":{\"target_price\":240,\"prob\":0.2,\"notes\":\"Leqembi and rare disease assets exceed expectations with solid margins.\"}},\"method_notes\":\"12M target uses a blended normalized forward P/E and EBITDA cross-check anchored to snapshot fundamentals and labeled assumptions; no sell-side targets used. Snapshot quote fields kept authoritative. BUY reflects ~10% 12M upside with moderate uncertainty. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "OpenAI o3", "risks": [ "Faster-than-expected MS franchise declines", "Slower Leqembi adoption or safety-related setbacks", "Pipeline trial or regulatory disappointments", "Pricing pressure and reimbursement changes", "Manufacturing or supply disruptions" ], "ticker": "BIIB", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "New products partly offset erosion and valuation rerates modestly.", "target_price": 198 }, "bear": { "prob": 0.25, "notes": "Legacy products decline faster and new launches underwhelm.", "target_price": 150 }, "bull": { "prob": 0.2, "notes": "Leqembi and rare disease assets exceed expectations with solid margins.", "target_price": 240 } }, "confidence": 0.64, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.03, "terminal_multiple": 13, "ebit_margin_target": 0.31 }, "key_drivers": [ { "driver": "Leqembi uptake and coverage", "impact": "HIGH", "direction": "POS" }, { "driver": "MS franchise erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "Spinraza stability", "impact": "MED", "direction": "POS" }, { "driver": "Skyclarys and rare disease growth", "impact": "MED", "direction": "POS" }, { "driver": "Cost discipline and margin retention", "impact": "MED", "direction": "POS" }, { "driver": "Pipeline readouts and approvals", "impact": "HIGH", "direction": "POS" }, { "driver": "Pricing and IRA reimbursement pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Deleveraging and capital allocation", "impact": "LOW", "direction": "POS" } ], "method_notes": "12M target uses a blended normalized forward P/E and EBITDA cross-check anchored to snapshot fundamentals and labeled assumptions; no sell-side targets used. Snapshot quote fields kept authoritative. BUY reflects ~10% 12M upside with moderate uncertainty. not investment advice", "current_price": 179.9, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E near 12x discounts much of legacy MS erosion.", "Leqembi, Skyclarys and biosimilars can stabilize the revenue mix.", "TTM operating margin above 33% supports resilient cash generation.", "EPS fell YoY and neuroscience launch execution risk remains elevated.", "Valuation looks modestly attractive, but uncertainty limits upside." ], "target_price_6m": 188, "target_price_12m": 198 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_030ce08a56664ae50069d7568d0aac8190888fbd2f68dd3a7b", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 49645, "createdAt": "2026-04-09T05:19:49.104Z", "usage": { "inputTokens": 2539, "outputTokens": 2387, "costUsd": 0.037861 } }, { "id": "cmnr12jqv02f2p65894af6php", "runId": "cmnr12jqs02eyp65872tje4fo", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Fundamental DCF Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"BIIB\",\n \"currency\": \"USD\",\n \"current_price\": 179.9,\n \"target_price_6m\": 195,\n \"target_price_12m\": 210,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"MS franchise generates stable cash flows despite competition.\",\n \"Spinraza and rare disease portfolio provide growth drivers.\",\n \"Forward P/E of 11.9 appears attractive vs history.\",\n \"Pipeline risks in neurology could delay approvals.\",\n \"Strong balance sheet supports strategic acquisitions.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"MS product revenue stability\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Spinraza and Skyclarys adoption\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Neurology pipeline success\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Patent expirations on key drugs\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competition in MS therapies\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory approval timelines\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Pricing pressure on biologics\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A and collaboration upside\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Patent cliffs for major MS drugs\",\n \"Clinical trial failures in pipeline\",\n \"Intense competition in neurology\",\n \"Regulatory delays for new drugs\",\n \"Drug pricing and reimbursement pressure\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.35,\n \"wacc\": 0.09,\n \"terminal_multiple\": 12\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 150,\n \"prob\": 0.25,\n \"notes\": \"Pipeline setbacks and faster MS revenue erosion.\"\n },\n \"base\": {\n \"target_price\": 210,\n \"prob\": 0.55,\n \"notes\": \"Steady core growth and modest pipeline contributions.\"\n },\n \"bull\": {\n \"target_price\": 265,\n \"prob\": 0.2,\n \"notes\": \"Successful launches and positive trial readouts.\"\n }\n },\n \"method_notes\": \"3y DCF with revenue CAGR, target EBIT margin and terminal multiple; base case yields 17% 12M upside. BUY per rubric. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Fundamental DCF Model", "risks": [ "Patent cliffs for major MS drugs", "Clinical trial failures in pipeline", "Intense competition in neurology", "Regulatory delays for new drugs", "Drug pricing and reimbursement pressure" ], "ticker": "BIIB", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady core growth and modest pipeline contributions.", "target_price": 210 }, "bear": { "prob": 0.25, "notes": "Pipeline setbacks and faster MS revenue erosion.", "target_price": 150 }, "bull": { "prob": 0.2, "notes": "Successful launches and positive trial readouts.", "target_price": 265 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.04, "terminal_multiple": 12, "ebit_margin_target": 0.35 }, "key_drivers": [ { "driver": "MS product revenue stability", "impact": "HIGH", "direction": "POS" }, { "driver": "Spinraza and Skyclarys adoption", "impact": "MED", "direction": "POS" }, { "driver": "Neurology pipeline success", "impact": "HIGH", "direction": "POS" }, { "driver": "Patent expirations on key drugs", "impact": "HIGH", "direction": "NEG" }, { "driver": "Competition in MS therapies", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory approval timelines", "impact": "MED", "direction": "NEG" }, { "driver": "Pricing pressure on biologics", "impact": "MED", "direction": "NEG" }, { "driver": "M&A and collaboration upside", "impact": "LOW", "direction": "POS" } ], "method_notes": "3y DCF with revenue CAGR, target EBIT margin and terminal multiple; base case yields 17% 12M upside. BUY per rubric. Not investment advice.", "current_price": 179.9, "recommendation": "BUY", "thesis_bullets": [ "MS franchise generates stable cash flows despite competition.", "Spinraza and rare disease portfolio provide growth drivers.", "Forward P/E of 11.9 appears attractive vs history.", "Pipeline risks in neurology could delay approvals.", "Strong balance sheet supports strategic acquisitions." ], "target_price_6m": 195, "target_price_12m": 210 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "48634ac8-2fc1-92a2-8795-a348ad8bac3b", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 20586, "createdAt": "2026-04-09T05:19:49.104Z", "usage": { "inputTokens": 2871, "outputTokens": 3584, "costUsd": 0.062373 } } ] } }